Brian Park, PharmD

Drug Information Specialist https://www.rheumatologyadvisor.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

Spondyloarthritis

Guselkumab Approved for the Treatment of Active Psoriatic Arthritis

Brian Park, PharmD

July 22, 2020

The FDA has approved Tremfya® for the treatment of adult patients with active psoriatic arthritis.

Practice Management

Immune Responses Observed in All Participants Who Received Moderna’s COVID-19 Vaccine Candidate

Brian Park, PharmD

July 20, 2020

Participants demonstrated high levels of neutralizing antibody activity that exceeded those seen in convalescent sera obtained from persons with confirmed COVID-19.

Vasculitis

Avacopan NDA Submitted for ANCA-Associated Vasculitis

Brian Park, PharmD

July 16, 2020

ChemoCentryx, Inc has submitted a NDA to the FDA for acavopan in the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.

General Rheumatology

Trial Investigating RA Drug Sarilumab for COVID-19 Stopped

Brian Park, PharmD

July 14, 2020

A phase 3 trial evaluating sarilumab, an interleukin-6 antagonist, in patients with COVID-19 requiring mechanical ventilation did not meet its primary and key secondary end points.

General Rheumatology

Adalimumab Biosimilar Gets FDA Approval for Rheumatic Diseases

Brian Park, PharmD

July 10, 2020

The FDA has approved Hulio® (adalimumab-fkjp; Mylan), a biosimilar to Humira® (adalimumab; AbbVie).

Systemic Lupus Erythematosus

Trial Investigating Ustekinumab for Systemic Lupus Erythematosus Discontinued

Brian Park, PharmD

July 1, 2020

Janssen has decided to discontinue the phase 3 LOTUS study evaluating ustekinumab (Stelara®) for the treatment of systemic lupus erythematosus.

General Rheumatology

Burosumab Approved for the Treatment of Tumor-Induced Osteomalacia

Brian Park, PharmD

June 24, 2020

The FDA has approved Crysvita for the treatment of fibroblast growth factor 23 (FGF23)-related hypophosphatemia in tumor-induced osteomalacia associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized in patients aged ≥2 years.

General Rheumatology

First Treatment for Adult-Onset Still Disease Gets FDA Approval

Brian Park, PharmD

June 19, 2020

The FDA has approved Ilaris for the treatment of active Still disease, including adult-onset Still disease.

Spondyloarthritis

Secukinumab Approved for Nonradiographic Axial Spondyloarthritis

Brian Park, PharmD

June 19, 2020

The FDA has approved Cosentyx® for the treatment of adults with active nonradiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation.

Rheumatoid Arthritis

Safety, Efficacy of Upadacitinib vs Abatacept in Patients With Moderate to Severe RA

Brian Park, PharmD

June 15, 2020

Results from the phase 3 SELECT-CHOICE study comparing treatment with upadacitinib to abatacept, a selective T cell costimulation modulator, in adults with moderate to severe active rheumatoid arthritis.

Next post in Rheumatoid Arthritis